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Morphine treatment  in  neonatal  period  on glutamate  uptake  in  spinal  synaptosomes.
Morphine group  showed  decreased  glutamate  uptake  in  medium  and  long-term.
This treatment  may  lead  to changes  in  spinal  glutamatergic  signaling.
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a  b  s  t  r  a  c  t
Morphine  exposure  during  the  neonatal  period  can  promote  changes  in  pain  signaling  pathways  that  can
be  expressed  as  an  increased  nociceptive  response  in adult  life. Glutamate  is  the major  excitatory  neu-
rotransmitter  in  primary  afferent  terminals  and  plays  a critical  role  in normal  spinal  excitatory  synaptic
transmission.  Considering  the importance  of  a  better  understanding  of  the  mechanisms  that  underlie
nociceptive  changes  throughout  the  life  course,  the  aim  of  this  study  was  investigate  the effects  of
repeated  morphine  administration  at postnatal  days  8 (P8)  to 14  (P14)  on  glutamate  uptake  in  spinal
synaptosomes  at P30  and  P60.  The  morphine  group  showed  decreased  [3H]-glutamate  uptake  as  com-lutamate uptake
pinal  synaptosomes
pared  to  control  groups  in  both  P30  and  P60.  These  ﬁndings  suggest  that morphine  exposure  in early  life
leads  to changes  in glutamatergic  signaling  at  least  until  the  60th  day  of age, which  may  lead  to  increased
levels  of  glutamate  in  the  spinal  synaptic  cleft  and,  consequently,  an  increased  nociceptive  response
in  adult  life.  Thus,  this  study  highlights  the  importance  of conducting  research  in  this  ﬁeld  to provide
a  comprehensive  knowledge  of  the  long-term  effects  of  early-life  morphine  treatment  on  nociceptive
pathways.. Introduction
Opioids are frequently used in critically ill children and neonates
or sedation and analgesia in the intensive care setting [1,3]. How-
ver, prolonged therapy often leads to tolerance and withdrawal
ymptoms when opioids are weaned or discontinued [11,36,40].
rosstalk between the pathways underlying opioid tolerance and
yperalgesia has also been proposed, suggesting that a common
ellular mechanism may  be causal in both conditions [18,20].
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Some rat studies have shown that morphine exposure during the
neonatal period can promote changes in pain signaling pathways
[32,37]. Sweitzer et al. [37] demonstrated that acute administration
in young rats produces spontaneous or precipitated withdrawal-
associated pain hypersensitivity. Recently, our group showed that
repeated morphine exposure in early life promotes a hyperalgesic
response to noxious events in the adult life of rats; this increased
nociceptive response was reversed by a NMDA receptor antagonist
[32], suggesting that early morphine exposure reduced the noci-
ceptive threshold due to possible adaptations in the glutamatergic
system.
Open access under the Elsevier OA license.Glutamate is a major excitatory neurotransmitter in primary
afferent terminals and plays a critical role in normal spinal excit-
atory synaptic transmission [8,17,33,43,46]. The homeostasis of
extracellular glutamate is tightly regulated by reuptake carried out
.
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Fig. 1. Repeated low-dose (5 g/day) morphine treatment from P8 to P14 decreased
[3H]-glutamate  uptake in spinal cord synaptosomes at P30 (Panel A) and P60
(Panel  B) (Student’s t-test, P = 0.019 for P30 and P = 0.04 for P60, n = 3–4 synap-2 J.R.  Rozisky et al. / Neurosc
y glutamate transporters (GTs) in the plasma membranes of both
eurons and glia [23,24], and it is crucial for nociception transmis-
ion and for the prevention of glutamate-induced neurotoxicity.
hanges in glutamate uptake have been implicated in peripheral
ervous system damage [14,19], neuropathic pain [35] and hyper-
lgesia [44,45].
Taking into account that morphine exposure in early life can lead
o changes in nociceptive behavior response in adult life, and that
his effect is reversed by administration of a glutamatergic recep-
or antagonist, this study sought to assess the long-term effect of
eonatal repeated morphine treatment on glutamate uptake in the
pinal synaptosomes of rats in adulthood.
. Materials and methods
At  birth, litters were standardized to contain up to 8 pups per
am, and pups remained with their mothers until 21 days of age.
ight-day-old male Wistar rats were divided into two groups:
aline control (C) and morphine-treated (M). Rats at P8 were cho-
en because it is accepted that animals in this age are at a similar
tage of neurological development to that of a human newborn
10]. It is also accepted that they are in a physiologically immature
tate [26], since this period is characterized by major developmen-
al changes in the brain and plasticity of the developing pain system
4,13,27]. Animal handling and all experiments were performed in
ccordance with international guidelines for animal welfare. Each
nimal received saline (control group) or morphine (5 g s.c. in the
id-scapular area; morphine group) starting at P8, then once daily
or 7 days. This dose was chosen on the basis of a previous study
y Rozisky et al. [30–32]. The experimental assays were performed
hen the animals were 30 and 60 days old.
Two (P30) and 5 weeks (P60) after the end of neonatal mor-
hine treatment the animals were decapitated. The spinal cord was
apidly removed, dissected out on ice, and gently homogenized in
0 vol. of ice-cold medium consisting of 320 mM sucrose, 1 mM
DTA, and 0.25 mM  dithiothreitol, pH 7.4, with a motor-driven
eﬂon-glass homogenizer. The synaptosomal fraction was isolated
n a discontinuous Percoll gradient, according to Dunkley et al. [9].
rotein concentration was measured using the Lowry method [16].
he entire spinal cord was used and a pool from two  rats was used
or each one synaptosomes assay, due to low yield of the enriched
raction in viable synaptosomes. The material was prepared fresh
aily and kept at 0–4 ◦C throughout the experiment.
Determination of Na+-dependent high-afﬁnity glutamate
ptake was performed as described by Leal et al. with minor
odiﬁcations [15]. Synaptosomal preparations were washed
wice through resuspension in 3 vol. of 300 mM sucrose with
5 mM Tris/acetate buffer (pH 7.4) and centrifugation at 13,000 × g
or 15 min  at 4 ◦C. The ﬁnal pellet was resuspended in 300 mM
ucrose with 15 mM Tris/acetate buffer (pH 7.4) and incubated
n HBSS (Hepes/Cl buffered salt solution) pH 7.4 (containing
7 mM HEPES, 133 mM NaCl, 2.4 mM KCl, 1.2 mM MgSO4, 1.2 mM
H2PO4, 12 mM glucose, 1.0 mM CaCl2) in the presence of 2 M of
-[3H] glutamic acid (PerkinElmer, Inc., MA,  USA, speciﬁc activity
.48–2.96 TBq/mmol) for 1 min  at 37 ◦C. The reaction was  stopped
y ﬁltration through GF/B glass microﬁber ﬁlters (Whatman).
he ﬁlters were washed three times with 3 ml  of ice-cold 15 mM
ris/acetate buffer (pH 7.4) in 155 mM ammonium acetate, and the
adioactivity retained on the ﬁlters was measured in a Wallac scin-
illation counter. Speciﬁc [3H] glutamate uptake was calculated as
he difference between uptake obtained in the incubation medium
s described above and uptake obtained with a similar incubation
edium containing choline chloride instead of NaCl (nonspeciﬁc
ptake). Na+-independent uptake was less than 10% of the total. All
easurements were made in triplicate. The results were expressedtosomes/group).  Bars represent mean ± SEM of glutamate uptake (percentage of
control group) in spinal cord synaptosomes. # represents a signiﬁcant difference
from  control group.
as percentage of [3H] glutamate uptake obtained on control group,
which was considered as 100%. The between-group comparisons
were performed with Student’s t-test for independent samples.
Differences were considered statistically signiﬁcant if P < 0.05.
3. Results
After repeated morphine treatment in early life, from P8 to P14,
[3H]-glutamate uptake in spinal synaptosomes was assessed at
P30 and P60. In both ages, animals that had received morphine
exhibited decreased [3H]-glutamate uptake as compared with
control animals that had received saline (P30: C = 100.0 ± 29.0%
of [3H] glutamate uptake, M = 12.96 ± 3.66% of [3H] glutamate
uptake obtained on control group, Student’s t-test, P = 0.019; P60:
C = 100.0 ± 22.63% of [3H] glutamate uptake, M = 31.37 ± 7.06% of
[3H] glutamate uptake obtained on control group; Student’s t-test,
P = 0.04, Fig. 1, Panels A and B).
4.  Discussion
In this study, once-daily, low-dose morphine administration in
early life, from P8 to P14, decreased [3H]-glutamate uptake in spinal
synaptosomes P30 and P60. This result suggests that opioid expo-
sure during development of the central nervous system leads to
long-lasting adaptations in the glutamatergic system.
Our  group has suggested that newborn rats may  be more sen-
sitive to low doses of morphine [31] because there is extensive
remodeling of opioid receptor expression in the ﬁrst 3 postna-
tal weeks [2,28,29]. At P14, spinal -opioid receptors (ORs) are
restricted to the dorsal horn, whereas they appear throughout the
spinal grey matter at P7, and the density of binding decreases in
the ﬁrst 3 postnatal weeks, with peak binding at P7, that then falls
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[J.R. Rozisky et al. / Neurosc
o adult levels by P21 [2]. This abundance of ORs in early postna-
al life could explain why exposure to morphine for 7 days, from
8 to P14, produces analgesia instead of tolerance [31]. Thus, the
reater expression of ORs at P7 in comparison to adult rats sug-
ests a more widespread effect of morphine, acting both directly
ithin the spinal cord and indirectly through larger termination
roﬁles of primary afferents (for a review, see [22]). This, coupled
ith the overexpression of excitatory amino acid receptors at the
rimary afferent-spinal cord synapse, supports a potential role for
ORs in the normal maturation of nociceptive circuitry; hence, dis-
uption of this by administration of exogenous opioid agonists may
ave detrimental consequences for the maturation of pain circuitry
38,39].
Some studies have shown that repeated opioid administra-
ion leads to possible neural adaptations that may  underlie
pioid-induced paradoxical pain [12,41,42]. Recently, we  showed
hat early morphine treatment increases nociceptive behavioral
esponses at P30 and P60 in a rat formalin tonic pain model.
emarkably, these behavioral changes were reverted by admin-
stration of a NMDA receptor antagonist in both ages, suggesting
irect involvement of the glutamatergic system in opioid-induced
ociception [32].
The  homeostasis of extracellular glutamate is tightly regulated
y glutamate transporters (GTs) in the plasma membranes of
oth neurons and glia [21]. The three glutamate transport pro-
ein subtypes isolated in the spinal cord (GLAST, GLT-1, EAAC1)
re considered essential to the maintenance of low resting levels of
lutamate (<1 mM)  and the prevention of overstimulation of glu-
amate receptors [21]. Notably, these glutamate transporters are
oncentrated in the superﬁcial dorsal horn of the spinal cord and
ccount for >80% of total glutamate transport [7]. Several studies
ndicate that GTs play a crucial role in the prevention of glutamate
eurotoxicity under both physiological and pathological conditions
[21], for review see [7]). The competitive opioid antagonist nalox-
ne decreases GLT-1 mRNA in brain regions and is involved in the
xpression of morphine withdrawal symptoms [25].
Recently, another study showed that morphine exposure in
dult rats leads to downregulation of spinal glutamate GLT-1
ransporter and is involved in the generation of opioid-induced
yperalgesia [6]. In addition, it bears stressing that synaptosomes
ave been widely used to investigate glutamate uptake; but the
peciﬁc glutamate transporters present in the synaptosomal prepa-
ation are still a matter of controversy. However, pharmacological
nalysis using different types of transporter blockers suggests that
his uptake aligns most closely with that of the GLT-1 transporter
34] (for a review, see [5,7]). Thus, one might suggest that the
ecreased [3H]-glutamate reuptake observed in spinal synapto-
omes after neonatal repeated morphine treatment (P30 and P60)
ould lead to increased extracellular glutamate levels in the spinal
ord synaptic cleft. This, in turn, may  increase excitatory amino
cid receptor activation (including NMDA). These considerations
an explain, at least in part, the increase in nociceptive behavioral
esponses at P30 and P60 induced by early-life morphine treatment
n this rat model.
In  conclusion, the ﬁndings presented here added new insights
o our previous studies [32], suggesting that repeated morphine
xposure in early life leads to long-lasting adaptations in gluta-
atergic signaling, due to a decrease in [3H]-glutamate uptake in
pinal synaptosomes at P30 and P60. This result may  be associ-
ted with increased levels of excitatory amino acids and potential
yperactivity of glutamatergic receptors, such as the NMDA recep-
or, which, in turn, leads to a hyperalgesic response in adult life.
urthermore, this study highlights the importance of continu-
ng research in this ﬁeld to provide comprehensive knowledge
f the long-term effects of morphine administration in early
ife.
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